suprane innöndunargufa, gegndreyptur stabbi
baxter medical ab* - desfluranum inn - innöndunargufa, gegndreyptur stabbi
eravac
laboratorios hipra, s.a. - inactivated rabbit haemorrhagic disease type 2 virus (rhdv2), strainv-1037 - Óvirkt veiru bóluefni - kanínur - fyrir virk bólusetningar af kanínum frá aldri 30 daga til að draga úr dauðsföll af völdum kanína blæðandi sjúkdómur tegund 2 veira (rhdv2).
startvac
laboratorios hipra s.a. - escherichia coli j5 inactivated, staphylococcus aureus (cp8) strain sp 140 inactivated, expressing slime-associated antigenic complex - Ónæmisfræðilegar rannsóknir á nautgripum - nautgripir (kýr og kviðar) - fyrir hjörð bólusetningar heilbrigt kýr og kvígur, í mjólkurvörur nautgripum naut með endurteknum kvenna vandamál, til að draga úr tíðni undir-klínískum kvenna og tíðni og alvarleika klínískum merki um klínískum kvenna af völdum Þegar sýkt merkið bit, kólígerlar og kóagúlasa-neikvæð stafýlókokkar. fullur bólusetningaráætlunin veldur ónæmi frá u.þ.b. 13. degi eftir fyrstu inndælingu þar til u.þ.b. dag 78 eftir þriðja inndælingu (jafngildir 130 dögum eftir fæðingu).
ubac
laboratorios hipra, s.a. - lipoteichoic sýru frá biofilm niður hluti af læknafélag uberis, álag 5616 - Ónæmisfræðilegar rannsóknir á nautgripum - nautgripir - fyrir virk bólusetningar heilbrigt kýr og kvígur til að draga úr tíðni klínískum spenalyf sýkingar af völdum læknafélag uberis, til að draga úr líkamsvöxt blóðkorna í læknafélag uberis jákvæð ársfjórðungi mjólk sýni og til að draga úr mjólk framleiðslu tap af völdum læknafélag uberis spenalyf sýkingum.
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svín - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
metronidazol normon innrennslislyf, lausn 5 mg/ml
laboratorios normon, s.a. - metronidazolum inn - innrennslislyf, lausn - 5 mg/ml
azitromicina normon filmuhúðuð tafla 500 mg
laboratorios normon s.a. - azithromycinum díhýdrat - filmuhúðuð tafla - 500 mg
ceftriaxona normon innrennslisstofn, lausn 2000 mg
laboratorios normon, s.a. - ceftriaxonum dínatríum - innrennslisstofn, lausn - 2000 mg
ceftriaxona normon stungulyfs-/innrennslisstofn og leysir, lausn 1000 mg
laboratorios normon, s.a. - ceftriaxonum dínatríum - stungulyfs-/innrennslisstofn og leysir, lausn - 1000 mg
dupixent
sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - umboðsmenn fyrir húðbólgu, að undanskildu barkstera - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.